- Home
- SACH vs ANL Comparison
SACH vs ANL Comparison
Compare SACH & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SACH | ANL |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 52.0M |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SACH | ANL |
|---|---|---|
| Price | $1.13 | $1.10 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 184.7K | 17.8K |
| Earning Date | 11-05-2025 | 04-20-2026 |
| Dividend Yield | ★ 17.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,906,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $0.88 |
| 52 Week High | $1.48 | $2.99 |
Technical Indicators
Market Signals| Indicator | SACH | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 63.85 | 36.49 |
| Support Level | $1.00 | $1.32 |
| Resistance Level | $1.14 | $1.59 |
| Average True Range (ATR) | 0.05 | 0.18 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 85.00 | 31.12 |
Price Performance
Historical ComparisonAbout SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.